Role of Activator Protein-1 Transcription Factor in Oral Cancer

S.C.      Srushti; M.N.      Kumar; S.      Hegde; S.      Biradar; S.J.      Shreedevi; S.J.      Prashanth; R.L.      Babu
Abstract

Cancer is a multi-step process involving alterations in epigenetic and genetic processes. Oral squamous cell carcinoma is a frequent oral malignancy that originates from the transformation of normal cells into malignant cells as a consequence of failures in a series of normal molecular and cellular processes. The mechanism of human carcinogenesis is often seen as a double-edged sword, with the body's system being thought to counteract the detrimental consequences of neoplastic cell proliferation while simultaneously promoting tumor development. Various transcription factors play a significant part in cancer regulation, with the activator protein-1 family of transcription factors (TFs) being the most prominent regulatory protein family. The Jun, Fos, ATF, and MAF protein families are all present in the AP-1 dimeric complex. While certain AP-1 proteins, including JunB and c-Fos, are known to be majorly oncogenic in function, experimental studies have shown that other AP-1 proteins, such as JunB and c-Fos, also play a critical role in tumor suppression. The aim of this review is to offer breakthrough information on the role of molecular mechanisms mediated by AP-1 TFs in tumor development and its environment.
Graphical Abstract

[1]
Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent  2001; 49(1): 72-82.
 [PMID:  12004680]

[2]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC Cancer Base No 10. Int J Cancer  2010; 127(12): 2893-917.

[3]
Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Lyon, France: IARC Press, International Agency for Research on Cancer  2007.IX. 

[4]
Pathak KA, Gupta S, Talole S, et al. Advanced squamous cell carcinoma of lower gingivobuccal complex: Patterns of spread and failure. Head Neck  2005; 27(7): 597-602.
 [http://dx.doi.org/10.1002/hed.20195] [PMID:  15825204]

[5]
Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: A cluster-randomised controlled trial. Lancet  2005; 365(9475): 1927-33.
 [http://dx.doi.org/10.1016/S0140-6736(05)66658-5] [PMID:  15936419]

[6]
Dikshit R, Gupta PC, Ramasundarahettige C, et al. Cancer mortality in India: A nationally representative survey. Lancet  2012; 379(9828): 1807-16.
 [http://dx.doi.org/10.1016/S0140-6736(12)60358-4] [PMID:  22460346]

[7]
Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol  2008; 44(1): 10-22.
 [http://dx.doi.org/10.1016/j.oraloncology.2007.06.011] [PMID:  17825602]

[8]
Thorat RV, Panse NS, Budukh AM, Dinshaw KA, Nene BM, Jayant K. Prevalence of tobacco use and tobacco-dependent cancers in males in the Rural Cancer Registry population at Barshi, India. Asian Pac J Cancer Prev  2009; 10(6): 1167-70.
 [PMID:  20192605]

[9]
Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol  2009; 45(4-5): 309-16.
 [http://dx.doi.org/10.1016/j.oraloncology.2008.06.002] [PMID:  18804401]

[10]
More Y, D’Cruz AK. Oral cancer: Review of current management strategies. Natl Med J India  2013; 26(3): 152-8.
 [PMID:  24476162]

[11]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet TJ, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin  2015; 65(2): 87-108.
 [http://dx.doi.org/10.3322/caac.21262] [PMID:  25651787]

[12]
Krishna A, Singh RK, Singh S, Verma P, Pal US, Tiwari S. Demographic risk factors, affected anatomical sites and clinicopathological profile for oral squamous cell carcinoma in a North Indian population. Asian Pac J Cancer Prev  2014; 15(16): 6755-60.
 [http://dx.doi.org/10.7314/APJCP.2014.15.16.6755] [PMID:  25169521]

[13]
Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE. Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg  2007; 65(2): 229-36.
 [http://dx.doi.org/10.1016/j.joms.2005.11.094] [PMID:  17236926]

[14]
Ferlay J. GLOBOCAN 2008 v1. 2, Cancer incidence and mortality world-wide: IARC Cancer Base No. 10. 2010. Available from:  http://globocan.iarc

[15]
Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury. Cancer  2004; 100(S9): 1995-2025.
 [http://dx.doi.org/10.1002/cncr.20162] [PMID:  15108222]

[16]
Holmstrup P. Oral erythroplakia-What is it? Oral Dis  2018; 24(1-2): 138-43.
 [http://dx.doi.org/10.1111/odi.12709] [PMID:  29480616]

[17]
Scully C, Bagan JV. Oral squamous cell carcinoma: Overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis  2009; 15(6): 388-99.
 [http://dx.doi.org/10.1111/j.1601-0825.2009.01563.x] [PMID:  19371401]

[18]
Barnes L, Eveson JW, Sidransky D, Reichart P, Eds. Pathology and
genetics of head and neck tumours. Lyon, France: IARC International
Agency for Research on Cancer 2005; IX 

[19]
Milian A, Bagan JV, Vera F. Squamous cell carcinoma of the oral cavity: A follow up study of 85 cases and analysis of prognostic variables. Bull Group Int Rech Sci Stomatol Odontol  1993; 36(1-2): 29-35.
 [PMID:  8318820]

[20]
Brandizzi D, Gandolfo M, Velazco ML, Cabrini RL, Lanfranchi H. Clinical features and evolution of oral cancer: A study of 274 cases in Buenos Aires, Argentina. Med Oral Patol Oral y Cirugia Bucal  2008; 13(9): E544-8.

[21]
Mashberg A, Merletti F, Boffetta P, et al. Appearance, site of occurrence, and physical and clinical characteristics of oral carcinoma in Tori-no, Italy. Cancer  1989; 63(12): 2522-7.
 [http://dx.doi.org/10.1002/1097-0142(19890615)63:12<2522:AID-CNCR2820631227>3.0.CO;2-X] [PMID:  2720601]

[22]
Sankaranarayanan R, Fernandez GL, Lence AJ, Pisani P, Rodriguez SA. Visual inspection in oral cancer screening in Cuba: A case-control study. Oral Oncol  2002; 38(2): 131-6.
 [http://dx.doi.org/10.1016/S1368-8375(01)00033-1] [PMID:  11854059]

[23]
Haya FM, Bagán JV, Murillo CJ, Poveda RR, Calabuig C. The prevalence of oral leukoplakia in 138 patients with oral squamous cell carcinoma. Oral Dis  2004; 10(6): 346-8.
 [http://dx.doi.org/10.1111/j.1601-0825.2004.01031.x] [PMID:  15533209]

[24]
Silverman S Jr. Early diagnosis of oral cancer. Cancer  1988; 62(S1): 1796-9.
 [http://dx.doi.org/10.1002/1097-0142(19881015)62:1+<1796:AID-CNCR2820621319>3.0.CO;2-E] [PMID:  3167796]

[25]
Silverman S. Oral cancer. Semin Dermatol  1994; 13(2): 132-7.

[26]
Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - Pathogenesis and analysis of 673 cases. Oral Oncol  2008; 44(8): 743-52.
 [http://dx.doi.org/10.1016/j.oraloncology.2007.09.012] [PMID:  18061527]

[27]
Chidzonga MM, Mahomva L. Sarcomas of the oral and maxillofacial region: A review of 88 cases in Zimbabwe. Br J Oral Maxillofac Surg  2007; 45(4): 317-8.
 [http://dx.doi.org/10.1016/j.bjoms.2005.11.008] [PMID:  16386339]

[28]
Shanti RM, O’Malley BW Jr. Surgical management of oral cancer. Dent Clin North Am  2018; 62(1): 77-86.
 [http://dx.doi.org/10.1016/j.cden.2017.08.005] [PMID:  29126495]

[29]
Schmitt CM, Buchbender M, Lutz R, Neukam FW. Oral implant survival in patients with Bisphosphonate (BP)/antiresorptive and radiation therapy and their impact on osteonecrosis of the jaws. A systematic review. Eur J Oral Implantol  2018; 11 (Suppl. 1): S93-S111.
 [PMID:  30109302]

[30]
Deng H, Sambrook PJ, Logan RM. The treatment of oral cancer: An overview for dental professionals. Aust Dent J  2011; 56(3): 244-252, 341.
 [http://dx.doi.org/10.1111/j.1834-7819.2011.01349.x] [PMID:  21884138]

[31]
Ong TK, Murphy C, Smith AB, Kanatas AN, Mitchell DA. Survival after surgery for oral cancer: A 30-year experience. Br J Oral Maxillofac Surg  2017; 55(9): 911-6.
 [http://dx.doi.org/10.1016/j.bjoms.2017.08.362] [PMID:  28918183]

[32]
Shah JP, Gil Z. Current concepts in management of oral cancer - Surgery. Oral Oncol  2009; 45(4-5): 394-401.
 [http://dx.doi.org/10.1016/j.oraloncology.2008.05.017] [PMID:  18674952]

[33]
Carneiro NJN, De-Menezes JD, Moura LB, Massucato EM, De-Andrade CR. Protocols for management of oral complications of chemotherapy and/or radiotherapy for oral cancer: Systematic review and meta-analysis current. Med Oral Patol Oral Cir Bucal  2017; 22(1): e15-23.
 [PMID:  27918734]

[34]
National Research Council. Biologic markers in immunotoxicology washington. National Academies Press 1992.

[35]
Rothman N, Stewart WF, Schulte PA. Incorporating biomarkers into cancer epidemiology: A matrix of biomarker and study design categories. Cancer Epidemiol Biomarkers Prev  1995; 4(4): 301-11.
 [PMID:  7655323]

[36]
Dadras SS, Lange AB, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol  2005; 18(9): 1232-42.
 [http://dx.doi.org/10.1038/modpathol.3800410] [PMID:  15803182]

[37]
Spielmann N, Wong DT. Saliva: Diagnostics and therapeutic perspectives. Oral Dis  2011; 17(4): 345-54.
 [http://dx.doi.org/10.1111/j.1601-0825.2010.01773.x] [PMID:  21122035]

[38]
McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev  1994; 3(8): 687-95.
 [PMID:  7881343]

[39]
Schwartz JL. Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit Rev Oral Biol Med  2000; 11(1): 92-122.
 [http://dx.doi.org/10.1177/10454411000110010501] [PMID:  10682902]

[40]
Tanaka T, Ishigamori R. Understanding carcinogenesis for fighting oral cancer. J Oncol  2011; 2011: 603740.
 [http://dx.doi.org/10.1155/2011/603740] [PMID:  21772845]

[41]
Sun Y, Liu N, Guan X, Wu H, Sun Z, Zeng H. Immunosuppression induced by chronic inflammation and the progression to oral squamous cell carcinoma. Mediators of Inflamm  2016; 2016: 5715719.
 [http://dx.doi.org/10.1155/2016/5715719]

[42]
Goertzen C, Mahdi H, Laliberte C, et al. Oral inflammation promotes oral squamous cell carcinoma invasion. Oncotarget  2018; 9(49): 29047-63.
 [http://dx.doi.org/10.18632/oncotarget.25540] [PMID:  30018735]

[43]
Liapatas S, Nakou M, Rontogianni D. Inflammatory infiltrate of chronic periradicular lesions: An immunohistochemical study. Int Endod J  2003; 36(7): 464-71.
 [http://dx.doi.org/10.1046/j.1365-2591.2003.00627.x] [PMID:  12823701]

[44]
Jeng JH, Wang YJ, Chiang BL, et al. Roles of keratinocyte inflammation in oral cancer: Regulating the prostaglandin E2, interleukin-6 and TNF- production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis  2003; 24(8): 1301-15.
 [http://dx.doi.org/10.1093/carcin/bgg083] [PMID:  12807728]

[45]
Nakano Y, Kobayashi W, Sugai S, Kimura H, Yagihashil S. Expression of tumor necrosis factor-α and interleukin-6 in oral squamous cell carcinoma. Jpn J Cancer Res  1999; 90(8): 858-66.
 [http://dx.doi.org/10.1111/j.1349-7006.1999.tb00827.x] [PMID:  10543258]

[46]
Brandwein GM, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: Histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol  2005; 29(2): 167-78.
 [http://dx.doi.org/10.1097/01.pas.0000149687.90710.21] [PMID:  15644773]

[47]
Prabhu SR, Wilson DF. Human papillomavirus and oral disease - Emerging evidence: A review. Aust Dent J  2013; 58(1): 2-10.
 [http://dx.doi.org/10.1111/adj.12020] [PMID:  23441786]

[48]
Meyer MS, Joshipura K, Giovannucci E, Michaud DS. A review of the relationship between tooth loss, periodontal disease, and cancer. Cancer Causes Control  2008; 19(9): 895-907.
 [http://dx.doi.org/10.1007/s10552-008-9163-4] [PMID:  18478344]

[49]
Libermann T, Zerbini L. Targeting transcription factors for cancer gene therapy. Curr Gene Ther  2006; 6(1): 17-33.
 [http://dx.doi.org/10.2174/156652306775515501] [PMID:  16475943]

[50]
Pei D. Regulation of pluripotency and reprogramming by transcription factors. J Biol Chem  2009; 284(6): 3365-9.
 [http://dx.doi.org/10.1074/jbc.R800063200] [PMID:  18819918]

[51]
Roeder RG, Rutter WJ. Multiple forms of DNA-dependent RNA polymerase in eukaryotic organisms. Nature  1969; 224(5216): 234-7.
 [http://dx.doi.org/10.1038/224234a0] [PMID:  5344598]

[52]
Kadonaga JT. Regulation of RNA polymerase II transcription by sequence-specific DNA binding factors. Cell  2004; 116(2): 247-57.
 [http://dx.doi.org/10.1016/S0092-8674(03)01078-X] [PMID:  14744435]

[53]
Ha PK, Benoit NE, Yochem R, et al. A transcriptional progression model for head and neck cancer. Clin Cancer Res  2003; 9(8): 3058-64.
 [PMID:  12912957]

[54]
Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs  2010; 15(3): 355-73.
 [http://dx.doi.org/10.1517/14728214.2010.497754] [PMID:  20557270]

[55]
Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: Implications for targeting transcription factors for cancer therapy. Clin Cancer Res  2009; 15(8): 2583-7.
 [http://dx.doi.org/10.1158/1078-0432.CCR-08-1137] [PMID:  19351775]

[56]
Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer  2002; 2(10): 740-9.
 [http://dx.doi.org/10.1038/nrc906] [PMID:  12360277]

[57]
Schoelch ML, Regezi JA, Dekker NP, et al. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol  1999; 35(3): 333-42.
 [http://dx.doi.org/10.1016/S1368-8375(98)00098-0] [PMID:  10621856]

[58]
Mishra R. Glycogen synthase kinase 3 beta: Can it be a target for oral cancer. Mol Cancer  2010; 9(1): 144.
 [http://dx.doi.org/10.1186/1476-4598-9-144] [PMID:  20537194]

[59]
De Sousa SOM, Mesquita RA, Pinto DS Jr, Gutkind S. Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. J Oral Pathol Med  2002; 31(2): 78-81.
 [http://dx.doi.org/10.1046/j.0904-2512.2001.10012.x] [PMID:  11896827]

[60]
Acay RR, Santos E, De Sousa SO. Correlation between c-Jun and human papillomavirus in oral premalignant and malignant lesions. Oral Oncol  2008; 44(7): 698-702.
 [http://dx.doi.org/10.1016/j.oraloncology.2007.09.007] [PMID:  18061529]

[61]
Zhang L, Pan HY, Zhong LP, et al. Fos-related activator-1 is overexpressed in oral squamous cell carcinoma and associated with tumor lymph node metastasis. J Oral Pathol Med  2010; 39(6): 470-6.
 [http://dx.doi.org/10.1111/j.1600-0714.2009.00869.x] [PMID:  20149058]

[62]
Mishra A, Bharti AC, Saluja D, Das BC. Transactivation and expression patterns of jun and Fos/AP-1 super-family proteins in human oral cancer. Int J Cancer  2010; 126(4): 819-29.
 [PMID:  19653276]

[63]
Shiratsuchi T, Ishibashi H, Shirasuna K. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. J Cell Physiol  2002; 193(3): 340-8.
 [http://dx.doi.org/10.1002/jcp.10181] [PMID:  12384986]

[64]
Chien MH, Ying TH, Hsieh YS, et al. Dioscorea nipponica Makino inhibits migration and invasion of human oral cancer HSC-3 cells by transcriptional inhibition of matrix metalloproteinase-2 through modulation of CREB and AP-1 activity. Food Chem Toxicol  2012; 50(3-4): 558-66.
 [http://dx.doi.org/10.1016/j.fct.2011.12.016] [PMID:  22210353]

[65]
Zenz R, Eferl R, Scheinecker C, et al. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther  2007; 10(1): 201.
 [http://dx.doi.org/10.1186/ar2338] [PMID:  18226189]

[66]
MacIntyre DA, Lee YS, Migale R, et al. Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice. FASEB J  2014; 28(5): 2358-68.
 [http://dx.doi.org/10.1096/fj.13-247783] [PMID:  24497579]

[67]
Angel P, Imagawa M, Chiu R, et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell  1987; 49(6): 729-39.
 [http://dx.doi.org/10.1016/0092-8674(87)90611-8] [PMID:  3034432]

[68]
Landschulz WH, Johnson PF, McKnight SL. The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science  1988; 240(4860): 1759-64.
 [http://dx.doi.org/10.1126/science.3289117] [PMID:  3289117]

[69]
Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol  2002; 4(5): E131-6.
 [http://dx.doi.org/10.1038/ncb0502-e131] [PMID:  11988758]

[70]
Zerial M, Toschi L, Ryseck RP, Schuermann M, Müller R, Bravo R. The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity. EMBO J  1989; 8(3): 805-13.
 [http://dx.doi.org/10.1002/j.1460-2075.1989.tb03441.x] [PMID:  2498083]

[71]
Chiu R, Angel P, Karin M. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell  1989; 59(6): 979-86.
 [http://dx.doi.org/10.1016/0092-8674(89)90754-X] [PMID:  2513128]

[72]
Zenz R, Wagner EF. Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol  2006; 38(7): 1043-9.
 [http://dx.doi.org/10.1016/j.biocel.2005.11.011] [PMID:  16423552]

[73]
Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta  1991; 1072(2-3): 129-57.
 [PMID:  1751545]

[74]
Atsaves V, Leventaki V, Rassidakis GZ, Claret FX. AP-1 transcription factors as regulators of immune responses in cancer. Cancers  2019; 11(7): 1037.
 [http://dx.doi.org/10.3390/cancers11071037] [PMID:  31340499]

[75]
Vesley ET. Framework for project twin stream’s value case and its application for environmental outcomes. Landcare Res Contract Rep  2009; 910-097.

[76]
Carlone DL, Richards JS. Functional interactions, phosphorylation, and levels of 3′,5′-cyclic adenosine monophosphate-regulatory element binding protein and steroidogenic factor-1 mediate hormone-regulated and constitutive expression of aromatase in gonadal cells. Mol Endocrinol  1997; 11(3): 292-304.
 [PMID:  9058376]

[77]
Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J  1999; 18(1): 188-97.
 [http://dx.doi.org/10.1093/emboj/18.1.188] [PMID:  9878062]

[78]
Stein B, Rahmsdorf HJ, Steffen A, Litfin M, Herrlich P. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol  1989; 9(11): 5169-81.
 [PMID:  2557547]

[79]
Wang S, Xu X, Xu F, et al. Combined expression of c-jun, c-fos, and p53 improves estimation of prognosis in oral squamous cell carcinoma. Cancer Invest  2016; 34(8): 393-400.
 [http://dx.doi.org/10.1080/07357907.2016.1217422] [PMID:  27558649]

[80]
Dong C, Ye DX, Zhang WB, Pan HY, Zhang ZY, Zhang L. Overexpression of c-fos promotes cell invasion and migration via CD44 pathway in oral squamous cell carcinoma. J Oral Pathol Med  2015; 44(5): 353-60.
 [http://dx.doi.org/10.1111/jop.12296] [PMID:  25482572]

[81]
Tischmeyer W, Grimm R. Activation of immediate early genes and memory formation. Cell Mol Life Sci  1999; 55(4): 564-74.
 [http://dx.doi.org/10.1007/s000180050315] [PMID:  10357227]

[82]
Shaywitz AJ, Greenberg ME. CREB: A stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem  1999; 68(1): 821-61.
 [http://dx.doi.org/10.1146/annurev.biochem.68.1.821] [PMID:  10872467]

[83]
He R, Du S, Lei T, Xie X, Wang Y. Glycogen synthase kinase 3β in tumorigenesis and oncotherapy. (Review) Oncol Rep  2020; 44(6): 2373-85.
 [http://dx.doi.org/10.3892/or.2020.7817] [PMID:  33125126]

[84]
Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med  1996; 74(10): 589-607.
 [http://dx.doi.org/10.1007/s001090050063] [PMID:  8912180]

[85]
Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene  2001; 20(19): 2390-400.
 [http://dx.doi.org/10.1038/sj.onc.1204383] [PMID:  11402335]

[86]
Ke LD, Adler SK, Follen MM, Clayman GL, Chen Z. Expression of human papillomavirus E7 mRNA in human oral and cervical neoplasia and cell lines supported by NIH grants R29 CA72427 (Z.C.), R55 DE OD10846 (K.A-S.), and P50DE11906 (K.A-S. and G.L.C.). Oral Oncol  1999; 35(4): 415-20.
 [http://dx.doi.org/10.1016/S1368-8375(99)00015-9] [PMID:  10645408]

[87]
Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol  2002; 22(13): 4952-64.
 [http://dx.doi.org/10.1128/MCB.22.13.4952-4964.2002] [PMID:  12052899]

[88]
Agarwal SK, Novotny EA, Crabtree JS, et al. Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA  2003; 100(19): 10770-5.
 [http://dx.doi.org/10.1073/pnas.1834524100] [PMID:  12960363]

[89]
Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NF-κB and Pdcd4. Trends Mol Med  2003; 9(1): 36-41.
 [http://dx.doi.org/10.1016/S1471-4914(02)00009-6] [PMID:  12524209]

[90]
Binétruy B, Smeal T, Karin M. Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain. Nature  1991; 351(6322): 122-7.
 [http://dx.doi.org/10.1038/351122a0] [PMID:  1903181]

[91]
Mathew B, Sankaranarayanan R, Nair PP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. Nutrition and Cancer  1995; 24(2): 197-202.

[92]
Neville BW, Damm DD, Allen C, Chi AC. Oral and maxillofacial pathology Amsterdam Elsevier Health Sciences.  2015.

[93]
Taghavi N, Yazdi I. Type of food and risk of oral cancer. Arch Iran Med  2007; 10(2): 227-32.

[94]
Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: Dynamic communities and host interactions. Nat Rev Microbiol  2018; 16(12): 745-59.
 [http://dx.doi.org/10.1038/s41579-018-0089-x] [PMID:  30301974]

[95]
Bravi F, Bosetti C, Filomeno M, et al. Foods, nutrients and the risk of oral and pharyngeal cancer. Br J Cancer  2013; 109(11): 2904-10.
 [http://dx.doi.org/10.1038/bjc.2013.667] [PMID:  24149181]

[96]
Nagesh R, Kiran Kumar KM, Naveen Kumar M, Patil RH, Sharma SC. Regulation of Jun and Fos AP-1 transcription factors by JNK MAPKs signaling cascade in areca nut extract treated KB cells. Biochem Biophys Rep  2021; 27: 101090.
 [http://dx.doi.org/10.1016/j.bbrep.2021.101090] [PMID:  34401529]

[97]
Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res  2001; 7(12): 4220-9.
 [PMID:  11751523]

[98]
Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem  1997; 272(15): 9962-70.
 [http://dx.doi.org/10.1074/jbc.272.15.9962] [PMID:  9092536]

[99]
Kim JW, Amin ARMR, Shin DM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res  2010; 3(8): 900-9.
 [http://dx.doi.org/10.1158/1940-6207.CAPR-09-0131] [PMID:  20663981]

[100]
Cassani B, Villablanca EJ, De Calisto J, Wang S, Mora JR. Vitamin A and immune regulation: Role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. Mol Aspects Med  2012; 33(1): 63-76.
 [http://dx.doi.org/10.1016/j.mam.2011.11.001] [PMID:  22120429]

[101]
Gudas LJ. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Differ  1992; 3(9): 655-62.
 [PMID:  1358181]

[102]
Lippman SM, Lee JJ, Martin JW, et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res  2006; 12(10): 3109-14.
 [http://dx.doi.org/10.1158/1078-0432.CCR-05-2636] [PMID:  16707609]

[103]
Uray IP, Dmitrovsky E, Brown PH. Retinoids and rexinoids in cancer prevention: From laboratory to clinic. Semin Oncol  2016; 43(1): 49-64.
 [http://dx.doi.org/10.1053/j.seminoncol.2015.09.002]

[104]
Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA  1997; 94(11): 5826-30.
 [http://dx.doi.org/10.1073/pnas.94.11.5826] [PMID:  9159159]

[105]
Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: Promise meets resistance. Oncogene  2003; 22(47): 7305-15.
 [http://dx.doi.org/10.1038/sj.onc.1206936] [PMID:  14576840]

[106]
Bertram JS, Bortkiewicz H. Dietary carotenoids inhibit neoplastic transformation and modulate gene expression in mouse and human cells. Am J Clin Nutr  1995; 62(6): 1327S-36S.
 [http://dx.doi.org/10.1093/ajcn/62.6.1327S] [PMID:  7495228]

[107]
Reddy GR, Vasudha KC, Lakshmaiah M, Kumar AN. Estimation of serum β-carotene levels in oral carcinoma. J Indian Acad Oral Med Radiol  2005; 17(4): 157.

[108]
Balaji S, Roy A. Beta-carotene-A versatile antioxidant in oral cancer: A review. Drug Invention Today  2020; 13(3): 398-403.

[109]
Palozza P, Serini S, Di Nicuolo F, Piccioni E, Calviello G. Prooxidant effects of β-carotene in cultured cells. Mol Aspects Med  2003; 24(6): 353-62.
 [http://dx.doi.org/10.1016/S0098-2997(03)00031-1] [PMID:  14585306]

[110]
Yang SS, Kim SG, Park BS, et al. Effect of β-carotene on cell growth inhibition of KB human oral cancer cells. Int J Oral Biol  2016; 41(3): 105-11.
 [http://dx.doi.org/10.11620/IJOB.2016.41.3.105]

[111]
Cho SO, Kim MH, Kim H. β-Carotene inhibits activation of NF-κB, activator protein-1, and STAT3 and regulates abnormal expression of some adipokines in 3T3-L1 adipocytes. J Cancer Prev  2018; 23(1): 37-43.
 [http://dx.doi.org/10.15430/JCP.2018.23.1.37] [PMID:  29629347]

[112]
Tanaka T, Tanaka M, Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: A review. Pathol Res Int  2011; 2011: 431246.
 [http://dx.doi.org/10.4061/2011/431246] [PMID:  21660266]

[113]
Lee MF, Chan CY, Hung HC, Chou IT, Yee AS, Huang CY. N-acetylcysteine (NAC) inhibits cell growth by mediating the EGFR/Akt/HMG Box-Containing Protein 1 (HBP1) signaling pathway in invasive oral cancer. Oral Oncol  2013; 49(2): 129-35.
 [http://dx.doi.org/10.1016/j.oraloncology.2012.08.003] [PMID:  22944050]

[114]
Schweikl H, Schmalz G, Spruss T. The induction of micronuclei in vitro by unpolymerized resin monomers. J Dent Res  2001; 80(7): 1615-20.
 [http://dx.doi.org/10.1177/00220345010800070401] [PMID:  11597020]

[115]
Tsai JY, Dillon JK. Chemoprevention in oral cancer.In: Improving Outcomes in Oral Cancer.  Cham Springer 2020; pp. 13-22.
 [http://dx.doi.org/10.1007/978-3-030-30094-4_2]

[116]
Qin X, Kuang H, Chen L, Wei S, Yu D, Liang F. Coexpression of growth differentiation factor 11 and reactive oxygen species in metastatic oral cancer and its role in inducing the epithelial to mesenchymal transition. Oral Surg Oral Med Oral Pathol Oral Radiol  2017; 123(6): 697-706.
 [http://dx.doi.org/10.1016/j.oooo.2017.03.010] [PMID:  28478937]

[117]
Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia. Medicine (Baltimore)  2018; 97(45): e13087.
 [http://dx.doi.org/10.1097/MD.0000000000013087] [PMID:  30407312]

[118]
Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J  2000; 16(3): 534-54.
 [http://dx.doi.org/10.1034/j.1399-3003.2000.016003534.x] [PMID:  11028671]

[119]
Bindu S, Mazumder S, Bandyopadhyay U. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol  2020; 180: 114147.
 [http://dx.doi.org/10.1016/j.bcp.2020.114147] [PMID:  32653589]

[120]
Sood S, Shiff SJ, Yang CS, Chen X. Selection of topically applied non-steroidal anti-inflammatory drugs for oral cancer chemoprevention. Oral Oncol  2005; 41(6): 562-7.
 [http://dx.doi.org/10.1016/j.oraloncology.2005.01.003] [PMID:  15975519]

[121]
Rathore K, Alexander M, Cekanova M. Piroxicam inhibits masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro. Transl Res  2014; 164(2): 158-68.
 [http://dx.doi.org/10.1016/j.trsl.2014.02.002] [PMID:  24631063]

[122]
Shklar G, Oh SK. Experimental basis for cancer prevention by vitamin E. Cancer Invest  2000; 18(3): 214-22.
 [http://dx.doi.org/10.3109/07357900009031826] [PMID:  10754990]

[123]
Iqubal MA, Khan M, Kumar P, Kumar A, Ajai K. Role of vitamin E in prevention of oral cancer: A review. J Clin Diagn Res  2014; 8(10): ZE05.
 [PMID:  25478472]

[124]
Stäuble B, Boscoboinik D, Tasinato A, Azzi A. Modulation of Activator Protein-1 (AP-1) transcription factor and protein kinase C by hydrogen peroxide and D-α-tocopherol in vascular smooth muscle cells. Eur J Biochem  1994; 226(2): 393-402.
 [http://dx.doi.org/10.1111/j.1432-1033.1994.tb20064.x] [PMID:  8001557]

[125]
Yin J, Thomas F, Lang JC, Chaum E. Modulation of oxidative stress responses in the human retinal pigment epithelium following treatment with vitamin C. J Cell Physiol  2011; 226(8): 2025-32.
 [http://dx.doi.org/10.1002/jcp.22532] [PMID:  21520054]

[126]
Garewal H. Chemoprevention of oral cancer. Eur J Cancer Prev  1994; 3(2): 101-8.
 [http://dx.doi.org/10.1097/00008469-199403000-00003] [PMID:  8019381]

[127]
Laljee RP, Muddaiah S, Salagundi B, et al. Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev  2013; 14(2): 1147-50.
 [http://dx.doi.org/10.7314/APJCP.2013.14.2.1147] [PMID:  23621203]

[128]
Ruan M, Thorn K, Liu S, et al. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma. Int J Oncol  2014; 44(6): 2103-10.
 [http://dx.doi.org/10.3892/ijo.2014.2356] [PMID:  24676671]

[129]
Shi J, Leng W, Zhao L, et al. Nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer: A dose–response meta analysis of prospective cohort studies  2017; 8: 99066. http://dx.doi.org/10.18632/oncotarget.21524

[130]
Baumeister P, Reiter M, Harréus U. Curcumin and other polyphenolic compounds in head and neck cancer chemoprevention. Oxid Med Cell Longev  2012; 2012: 902716.
 [http://dx.doi.org/10.1155/2012/902716] [PMID:  22690273]

[131]
Suhail S, Gupta S, Kumar V, Gupta OP. Role of curcumin in oral cancer prevention. Frac-tal Geometry and Nonlinear Anal in Med and Biol  2015; 1(3): 120-2.

[132]
Mishra A, Kumar R, Tyagi A, et al. Curcumin modulates cellular AP-1, NF-kB, and HPV16 E6 proteins in oral cancer. Ecancermedicalscience  2015; 9: 525.
 [http://dx.doi.org/10.3332/ecancer.2015.525] [PMID:  25932049]

[133]
Alam M, Kashyap T, Pramanik KK, Singh AK, Nagini S, Mishra R. The elevated activation of NFκB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance. Clin Oral Investig  2017; 21(9): 2721-31.
 [http://dx.doi.org/10.1007/s00784-017-2074-6] [PMID:  28233171]

[134]
Bano N, Yadav M, Das BC. Differential inhibitory effects of curcumin between HPV+ ve and HPV–ve oral cancer stem cells. Front Oncol  2018; 8: 412.
 [http://dx.doi.org/10.3389/fonc.2018.00412] [PMID:  30319975]

[135]
Tewari D, Nabavi SF, Nabavi SM, et al. Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention. Pharmacol Res  2018; 128: 366-75.
 [http://dx.doi.org/10.1016/j.phrs.2017.09.014] [PMID:  28951297]

[136]
Bierhaus A, Zhang Y, Quehenberger P, et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κ B. Thromb Haemost  1997; 77(4): 772-82.
 [http://dx.doi.org/10.1055/s-0038-1656049] [PMID:  9134658]

[137]
Chen YR, Tan TH. Inhibition of the c-Jun N-Terminal Kinase (JNK) signaling pathway by curcumin. Oncogene  1998; 17(2): 173-8.
 [http://dx.doi.org/10.1038/sj.onc.1201941] [PMID:  9674701]

[138]
Hassan F, Rehman MS, Khan MS, et al. Curcumin as an alternative epigenetic modulator: Mechanism of action and potential effects. Front Genet  2019; 10: 514.
 [http://dx.doi.org/10.3389/fgene.2019.00514] [PMID:  31214247]

[139]
Mangalath U, Mikacha MSK, Abdul Khadar AH, Aslam SA, Francis PG, Kalathingal J. Recent trends in prevention of oral cancer. J Int Soc Prev Community Dent  2014; 4(6): 131.
 [http://dx.doi.org/10.4103/2231-0762.149018] [PMID:  25625069]

[140]
Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res  2003; 82(1): 11-6.
 [http://dx.doi.org/10.1177/154405910308200104] [PMID:  12508038]

[141]
Kumar MS, Masthan KM, Babu NA, Dash KC. Gene therapy in oral cancer: A review. J Clin Diagn Res  2013; 7(6): 1261-3.
 [http://dx.doi.org/10.7860/JCDR/2013/5412.3071] [PMID:  23905156]

[142]
Otero RE, García GA, Barros AF, Torres EM, Gándara RJM, Somoza MM. DNA microarrays in oral cancer. Med Oral  2004; 9(4): 288-92.
 [PMID:  15292866]

[143]
Azzazy HME, Mansour MMH, Kazmierczak SC. Nanodiagnostics: A new frontier for clinical laboratory medicine. Clin Chem  2006; 52(7): 1238-46.
 [http://dx.doi.org/10.1373/clinchem.2006.066654] [PMID:  16709623]

[144]
Morozova O, Marra MA. Applications of next-generation sequencing technologies in functional genomics. Genomics  2008; 92(5): 255-64.
 [http://dx.doi.org/10.1016/j.ygeno.2008.07.001] [PMID:  18703132]
Cite As
Current Cancer Therapy Reviews

Role of Activator Protein-1 Transcription Factor in Oral Cancer

Abstract

Graphical Abstract
